Traut Mario, Haufe Christoph C, Eismann Ulrike, Deppisch Reinhold M, Stein Gunter, Wolf Gunter
Department of Internal Medicine III, University of Jena, Jena, Germany.
Blood Purif. 2007;25(5-6):432-40. doi: 10.1159/000110069. Epub 2007 Oct 23.
Patients on long-term dialysis eventually develop amyloid deposits with beta2-microglobulin as a predominant component. Although several studies have suggested that high-flux membranes reduce beta2-microglobulin in plasma compared with low-flux dialyzers, the mechanisms underlying this observation are still discussed.
We revisited this important subject and measured beta2-microglobulin in the plasma of healthy individuals (n = 8), and patients undergoing hemodialysis (n = 20) who for assigned periods of time were either treated with a low-flux membrane (cuprophan) or high-flux (polyamide) dialyzer with an ELISA. The number of blood cells was determined by FACS. Beta2-microglobulin was also measured on the surface of granulocytes, lymphocytes, and monocytes before, directly after, and 4 h after hemodialysis. Expression of beta2-microglobulin, c-fos, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 mRNA was determined in whole blood samples with quantitative RT-PCR using an internal standard in parallel. In the second part of the study, patients were assigned in a two-group cross-over design either to low- or high-flux dialyzers (n = 9 in each group), and dialyzer membranes were changed every 4 weeks for two consecutive periods. Serum beta2-microglobulin concentrations were measured at the end of each period.
Healthy controls had a low plasma beta2-microglobulin level of 1.2 +/- 0.3 mg/l. Before hemodialysis, patients on low-flux dialyzers had a plasma beta2-microglobulin level of 42.0 +/- 14.0 mg/l, patients treated with high-flux dialyzers 21.5 +/- 10.8 mg/l (p < 0.05 vs. low-flux dialyzers). In contrast, there was no significant difference in plasma concentrations of active transforming growth factor-beta1 with the two different membrane types. The difference in serum beta2-microglobulin between low- and high-flux membranes was more prominent directly after hemodialysis as well as 4 h after hemodialysis compared with the values directly before the start of treatment. At all studied time-points, leukocytes and platelets were significantly higher in patients on low-flux membranes. Healthy control persons exhibited a significantly higher amount of beta2-microglobulin bound to granulocytes, lymphocytes, and monocytes compared with dialysis patients. Interestingly, beta2-microglobulin bound to granulocytes, lymphocytes, and monocytes was significantly increased in patients treated with high-flux membranes compared with low-flux filters. Quantitative RT-PCR revealed no significant difference in beta2-microglobulin expression in whole blood before hemodialysis, directly after hemodialysis, and 4 h after hemodialysis. However, TNF-alpha and c-fos transcripts were significantly higher in whole blood obtained from patients treated with low-flux membranes compared to high-flux dialyzers. The two-group cross-over study over three periods of 4 weeks revealed that switching from low-flux to high-flux dialyzers significantly reduced serum beta2-microglobulin levels.
Patients treated with a polyamide high-flux membrane had lower beta2-microglobulin concentrations compared with those patients on low-flux dialyzers. This difference might not be mediated by an increase in beta2-microglobulin mRNA, but may be caused by less beta2-microglobulin released from the blood cells in patients treated with high-flux dialyzers, in addition to a better beta2-microglobulin clearance.
长期透析患者最终会形成以β2-微球蛋白为主要成分的淀粉样沉积物。尽管多项研究表明,与低通量透析器相比,高通量膜可降低血浆中的β2-微球蛋白,但这一现象背后的机制仍在探讨中。
我们重新审视了这个重要课题,使用酶联免疫吸附测定法(ELISA)测量了健康个体(n = 8)以及接受血液透析的患者(n = 20)血浆中的β2-微球蛋白。这些接受血液透析的患者在指定时间段内分别使用低通量膜(铜仿膜)或高通量(聚酰胺)透析器进行治疗。通过荧光激活细胞分选术(FACS)测定血细胞数量。在血液透析前、透析刚结束后以及透析后4小时,还对粒细胞、淋巴细胞和单核细胞表面的β2-微球蛋白进行了测量。使用内标通过定量逆转录聚合酶链反应(RT-PCR)在全血样本中平行测定β2-微球蛋白、c-fos、肿瘤坏死因子-α(TNF-α)和白细胞介素-1 mRNA的表达。在研究的第二部分,患者被分配到两组交叉设计中,分别使用低通量或高通量透析器(每组n = 9),透析器膜每4周更换一次,连续进行两个周期。在每个周期结束时测量血清β2-微球蛋白浓度。
健康对照组血浆β2-微球蛋白水平较低,为1.2±0.3 mg/l。血液透析前,使用低通量透析器的患者血浆β2-微球蛋白水平为42.0±14.0 mg/l,使用高通量透析器治疗的患者为21.5±10.8 mg/l(与低通量透析器相比,p < 0.05)。相比之下,两种不同膜类型的活性转化生长因子-β1血浆浓度没有显著差异。与治疗开始前的值相比,低通量和高通量膜之间血清β2-微球蛋白的差异在血液透析刚结束后以及透析后4小时更为明显。在所有研究的时间点,使用低通量膜的患者白细胞和血小板显著更高。与透析患者相比,健康对照者与粒细胞、淋巴细胞和单核细胞结合的β2-微球蛋白量显著更高。有趣的是,与低通量滤器相比,使用高通量膜治疗的患者与粒细胞、淋巴细胞和单核细胞结合的β2-微球蛋白显著增加。定量RT-PCR显示血液透析前、透析刚结束后以及透析后4小时全血中β2-微球蛋白表达没有显著差异。然而,与高通量透析器相比,从使用低通量膜治疗的患者获得的全血中TNF-α和c-fos转录本显著更高。为期4周的三个周期的两组交叉研究表明,从低通量透析器转换为高通量透析器可显著降低血清β2-微球蛋白水平。
与使用低通量透析器的患者相比,使用聚酰胺高通量膜治疗的患者β2-微球蛋白浓度更低。这种差异可能不是由β2-微球蛋白mRNA增加介导的,而是除了更好的β2-微球蛋白清除率外,可能是由于使用高通量透析器治疗的患者血细胞释放的β2-微球蛋白减少所致。